News Image

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Provided By GlobeNewswire

Last update: Nov 4, 2024

SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy’s Laboratories Ltd.

Read more at globenewswire.com

JOURNEY MEDICAL CORP

NASDAQ:DERM (5/28/2025, 4:30:02 PM)

After market: 7.87 0 (0%)

7.87

+0.1 (+1.29%)


FORTRESS BIOTECH INC

NASDAQ:FBIO (5/28/2025, 4:30:40 PM)

After market: 1.8799 -0.02 (-1.06%)

1.9

+0.07 (+3.83%)



Find more stocks in the Stock Screener

Follow ChartMill for more